Orchestra BioMed Holdings, Inc. (OBIO) — Financial statements
Income statement, balance sheet, and cash flow for Orchestra BioMed Holdings, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 33↑1169.2% | 3↓4.4% | 3↓21.9% | 4↑551.8% | -0.78 | |
| Cost of Revenue | 0.35↑73.3% | 0.20↑9.7% | 0.19↓42.2% | 0.32↑61.8% | 0.20 | |
| Gross Profit | 33↑1261.1% | 2↓5.4% | 3↓19.8% | 3↑427.3% | -0.98 | |
| Operating Expenses | ||||||
| R&D Expenses | 58↑35.9% | 43↑26.6% | 34↑54.1% | 22↑70.2% | 13 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 27↑11.8% | 24↑18.1% | 20↑45.5% | 14↑75.6% | 8 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 85↑27.3% | 67↑23.4% | 54↑50.8% | 36↑72.3% | 21 | |
| Total Costs & Expenses | 85↑27.4% | 67↑23.4% | 54↑49.9% | 36↑72.2% | 21 | |
| Operating Results | ||||||
| Operating Income | -52↑19.4% | -64↓24.8% | -52↓57.7% | -33↓49.8% | -22 | |
| Depreciation & Amortization | 0.33↑6.2% | 0.31↑7.3% | 0.29↑29.3% | 0.22↑22.7% | 0.18 | |
| EBITDA | -51↑19.6% | -64↓24.9% | -51↓57.9% | -32↓50.0% | -22 | |
| EBIT | -52↑19.4% | -64↓24.8% | -52↓57.7% | -33↓49.8% | -22 | |
| Interest & Other Income | ||||||
| Net Interest Income | -1↓134.2% | 3↓12.8% | 4↑7598.0% | 0.05↑105.4% | -0.93 | |
| Interest Income | 0.00↓100.0% | 3↓12.8% | 4↑7598.0% | 0.05 | 0.00 | |
| Interest Expense | 1 | 0.00 | 0.00 | 0.00↓100.0% | 0.93 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -0.89↓127.3% | 3↑37.3% | 2↑350.9% | -0.95↑21.7% | -1 | |
| Income Before Tax | -53↑13.6% | -61↓24.2% | -49↓46.2% | -34↓46.0% | -23 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -53↑13.6% | -61↓24.2% | -49↓46.2% | -34↓46.0% | -23 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -53↑13.6% | -61↓24.2% | -49↓46.2% | -34↓46.0% | -23 | |
| Bottom-Line Net Income | -53↑13.2% | -61↓24.2% | -49↓46.2% | -34↓8773.3% | -0.38 | |
| EPS (Basic) | -1.11↑33.1% | -1.66↓12.2% | -1.48↓12.1% | -1.32↓7035.1% | -0.02 | |
| EPS (Diluted) | -1.11↑33.1% | -1.66↓12.2% | -1.48↓12.1% | -1.32↓7035.1% | -0.02 | |
| Weighted Average Shares | 38,393↑104168.4% | 37↑10.8% | 33↑30.4% | 25↑24.6% | 20 | |
| Weighted Average Diluted Shares | 38,393↑104168.4% | 37↑10.8% | 33↑30.4% | 25↑24.6% | 20 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.